Uncover key drivers, emerging technologies, and competitive movements shaping the emerging infectious disease diagnostics market from 2026–2035 with trusted insights from The Business Research Company
What size range is anticipated for the Emerging Infectious Disease Diagnostics Market from 2026 to 2030?
The emerging infectious disease diagnostics market has experienced substantial growth in recent years. It is projected to increase from $24.34 billion in 2025 to $26.75 billion in 2026, at a compound annual growth rate (CAGR) of 9.9%. Historically, this growth can be attributed to the rising frequency of infectious disease outbreaks, the expansion of public health surveillance programs, increased investments in laboratory infrastructure, a growing demand for rapid diagnostic solutions, and advancements in molecular testing technologies.
The market size for emerging infectious disease diagnostics is poised for robust expansion in the coming years. This sector is projected to reach $38.54 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.6%. This anticipated growth is largely attributed to a heightened focus on pandemic readiness, the increasing uptake of next-generation sequencing diagnostics, the expansion of decentralized testing frameworks, the growing incorporation of AI-driven diagnostic analytics, and increased government financial support for disease monitoring. Significant trends during this forecast period encompass the wider deployment of rapid molecular diagnostic platforms, a surge in the adoption of point-of-care testing solutions, the expanding integration of genomic surveillance tools, the broader application of multiplex diagnostic assays, and an intensified emphasis on the early detection of outbreaks.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20548&type=smp
What Drivers Are Affecting Demand In The Emerging Infectious Disease Diagnostics Market?
The increasing prevalence of zoonotic diseases is anticipated to drive the expansion of the emerging infectious disease diagnostics market in the future. Zoonotic diseases are infections capable of transmitting from animals to humans, caused by bacteria, viruses, parasites, or fungi. The heightened occurrence of these diseases is primarily attributable to more frequent human-wildlife interactions, habitat destruction, and global travel, all of which facilitate pathogen transmission across species. Emerging infectious disease diagnostics aid in managing zoonotic diseases by enabling prompt detection and accurate identification of pathogens, thereby allowing for swift intervention, effective treatment, and better containment of disease outbreaks, ultimately reducing animal-to-human transmission. For instance, in June 2025, according to the Centers for Disease Control and Prevention, a US-based government public-health agency, 48 states and the District of Columbia reported 2,770 human arboviral disease cases in 2023, an increase from 1,247 cases in 2022. This included 2,022 hospitalizations (73%) and 208 deaths (8%), with West Nile virus being the most commonly reported domestic arboviral disease in 2023, accounting for 2,628 cases (95%). Consequently, the rising incidence of zoonotic diseases is a significant driver for the emerging infectious disease diagnostics market.
Which Segments Are Gaining Traction In The Emerging Infectious Disease Diagnostics Market?
The emerging infectious disease diagnostics market covered in this report is segmented –
1) By Infection Type: Viral, Bacterial, Fungal, Other Infections
2) By Disease Type: Respiratory Infections, Gastrointestinal Infections, Sexually Transmitted Infections (STIs), Other Disease Types
3) By Technology: Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), Next-Generation Sequencing (NGS), Immunodiagnostics, Other Technologies
4) By Application: Laboratory Testing, Point-of-Care Testing
5) By End-User: Hospitals And Clinics, Diagnostics Laboratories, Other End-Users
Subsegments:
1) By Viral: Respiratory Viruses, Hepatitis Viruses, HIV and Retroviruses, Arboviruses, Herpesviruses, Gastrointestinal Viruses, Emerging Viral Infections
2) By Bacterial: Tuberculosis (TB), Methicillin-Resistant Staphylococcus Aureus (MRSA), Escherichia Coli (E. coli) Infections, Streptococcus and Pneumococcus Infections, Clostridium Infections, Neisseria, Emerging Drug-Resistant Bacteria
3) By Fungal: Candidiasis, Aspergillosis, Cryptococcosis, Histoplasmosis, Coccidioidomycosis, Pneumocystis Pneumonia (PCP), Emerging Fungal Infections
4) By Other Infections: Parasitic Infections, Protozoan Infections, Prion Diseases, Helminthic Infections, Non-Pathogenic or Environmental Infections
What Trends Are Driving The Growth Trajectory Of The Emerging Infectious Disease Diagnostics Market?
Leading companies in the emerging infectious disease diagnostics market are concentrating on creating innovative solutions, such as temperature-activated generation of signal (TAGS) technology, to improve rapid detection, high-throughput screening, and outbreak response capabilities. TAGS technology is an advanced multiplex PCR method that utilizes controlled temperature activation to produce optical signals for the simultaneous identification of various pathogens from a single sample, thereby enabling broad syndromic testing, quicker turnaround times, and optimized laboratory workflows. As an illustration, in September 2024, F. Hoffmann-La Roche AG, a diagnostics and biotechnology firm from Switzerland, introduced the cobas Respiratory flex test. This TAGS-powered molecular diagnostic is designed to identify up to 12 common respiratory viruses from one patient sample, incorporating automated high-throughput analysis, flexible pathogen panel configuration, and compatibility with cobas 5800, 6800, and 8800 systems. The cobas Respiratory flex enhances the timely detection of infectious agents, strengthens clinical decision-making, and contributes to better preparedness for emerging disease threats.
Who Are The Major Companies Operating In The Emerging Infectious Disease Diagnostics Market?
Major companies operating in the emerging infectious disease diagnostics market are Roche Diagnostics, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers, Becton Dickinson and Company, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Agilent Technologies Inc., Hologic Inc., Illumina Inc., bioMérieux SA, QuidelOrtho Corporation, Bio-Rad Laboratories, Inc., Qiagen N.V., DiaSorin S.p.A., Randox Laboratories Ltd., Meridian Bioscience Inc., Sekisui Diagnostics LLC, Copan Diagnostics, Co-Diagnostics Inc., T2 Biosystems Inc.
Access The Complete Report For Deeper Market Insights:
Which Global Regions Are Shaping The Competitive Landscape Of The Emerging Infectious Disease Diagnostics Market?
North America was the largest region in the emerging infectious disease diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the emerging infectious disease diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Emerging Infectious Disease Diagnostics Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=20548&type=smp
Browse Through More Reports Similar to the Global Emerging Infectious Disease Diagnostics Market 2026, By The Business Research Company
Cancer Diagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report
Transplant Diagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/transplant-diagnostics-global-market-report
Blood Transfusion Diagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/blood-transfusion-diagnostics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model